Type I interferons (IFNs) are a first line of defence against viral infections. Upon infection, a first small wave of early type I IFN, mainly IFN-β and particularly IFN-α4, are induced and bind to the type I IFN receptor (IFNAR) to amplify the IFN response. It was shown for several viruses that robust type I IFN responses require this positive feedback loop via the IFNAR. Recently, we showed that infection of IFNAR knockout mice with the orthomyxovirus Thogoto virus lacking the ML open reading frame (THOV(ML-)) results in the expression of unexpected high amounts of type I IFN. To investigate if IFNAR-independent IFN responses are unique for THOV(ML-), we performed infection experiments with several negative-strand RNA viruses using different routes and dosages for infection. A variety of these viruses induced type I IFN responses IFNAR-independently when using the intraperitoneal (i.p.) route for infection. In vitro studies demonstrated that myeloid dendritic cells (mDC) are capable of producing IFNAR-independent IFN-α responses that are dependent on the expression of the adaptor protein mitochondrial antiviral-signalling protein (MAVS) whereas pDC where entirely depending on the IFNAR feedback loop in vitro. Thus, depending on dose and route of infection, the IFNAR feedback loop is not strictly necessary for robust type I IFN expression and an IFNAR-independent type I IFN production might be the rule rather than the exception for infections with numerous negative-strand RNA viruses.
Fitzgerald-BocarslyP, FengD. The role of type I interferon production by dendritic cells in host defense. Biochimie2007; 89:843–855 [View Article] [PubMed]
SchulzO, PichlmairA, RehwinkelJ, RogersNC, ScheunerD et al. Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity. Cell Host Microbe2010; 7:354–361 [View Article] [PubMed]
SuL, DavidM. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem2000; 275:12661–12666 [View Article] [PubMed]
HondaK, TakaokaA, TaniguchiT. Type I interferon corrected gene induction by the interferon regulatory factor family of transcription factors. Immunity2006; 25:349–360 [View Article] [PubMed]
SatoM, HataN, AsagiriM, NakayaT, TaniguchiT et al. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett1998; 441:106–110 [View Article] [PubMed]
DieboldSS, KaishoT, HemmiH, AkiraS, Reis eSousa C. Innate antiviral responses by means of tlr7-mediated recognition of single-stranded RNA. Science2004; 303:1529–1531 [View Article] [PubMed]
SiegalFP, KadowakiN, ShodellM, Fitzgerald-BocarslyPA, ShahK et al. The nature of the principal type 1 interferon-producing cells in human blood. Science1999; 284:1835–1837 [View Article] [PubMed]
HidmarkAS, McInerneyGM, NordströmEKL, DouagiI, WernerKM et al. Early alpha/beta interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88. J Virol2005; 79:10376–10385 [View Article] [PubMed]
GitlinL, BarchetW, GilfillanS, CellaM, BeutlerB et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A2006; 103:8459–8464 [View Article] [PubMed]
MüllerU, SteinhoffU, ReisLF, HemmiS, PavlovicJ et al. Functional role of type I and type II interferons in antiviral defense. Science1994; 264:1918–1921 [View Article] [PubMed]
HwangSY, HertzogPJ, HollandKA, SumarsonoSH, TymmsMJ et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci U S A1995; 92:11284–11288 [View Article] [PubMed]
GoritzkaM, DurantLR, PereiraC, Salek-ArdakaniS, OpenshawPJM et al. Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol2014; 88:6128–6136 [View Article] [PubMed]
KumagaiY, KumarH, KoyamaS, KawaiT, TakeuchiO et al. Cutting edge: Tlr-dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for ifn- product(alpha)smacproinendritic ceplasmacytodendritic. J Immunol2009; 182:3960–3964 [View Article] [PubMed]
TailorP, TamuraT, KongHJ, KubotaT, KubotaM et al. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity2007; 27:228–239 [View Article] [PubMed]
KernbauerE, MaierV, RauchI, MüllerM, DeckerT. Route of infection determines the impact of type I interferons on innate immunity to Listeria monocytogenes. PLoS One2013; 8:e65007 [View Article] [PubMed]
DemarsA, LisonA, MachelartA, Van VyveM, PotembergG et al. Route of infection strongly impacts the host-pathogen relationship. Front Immunol2019; 10:1589 [View Article] [PubMed]
KumagaiY, TakeuchiO, KatoH, KumarH, MatsuiK et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity2007; 27:240–252 [View Article] [PubMed]
KochsG, AnzagheM, KronhartS, WagnerV, GogeschP et al. In vivo conditions enable ifnar-independent type I interferon production by peritoneal cd11b+ cells upon Thogoto virus infection. J Virol2016; 90:9330–9337 [View Article] [PubMed]
van den BroekMF, MüllerU, HuangS, AguetM, ZinkernagelRM. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol1995; 69:4792–4796 [View Article] [PubMed]
AdachiO, KawaiT, TakedaK, MatsumotoM, TsutsuiH et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity1998; 9:143–150 [View Article] [PubMed]
MichalletMC, MeylanE, ErmolaevaMA, VazquezJ, RebsamenM et al. TRADD protein is an essential component of the rig-like helicase antiviral pathway. Immunity2008; 28:651–661 [View Article] [PubMed]
StojdlDF, LichtyBD, tenOeverBR, PatersonJM, PowerAT et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell2003; 4:263–275 [View Article] [PubMed]
BouloyM, JanzenC, VialatP, KhunH, PavlovicJ et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol2001; 75:1371–1377 [View Article] [PubMed]
KochsG, KoernerI, ThielL, KothlowS, KaspersB et al. Properties of H7N7 influenza A virus strain SC35M lacking interferon antagonist NS1 in mice and chickens. J Gen Virol2007; 88:1403–1409 [View Article] [PubMed]
BaslerCF, WangX, MühlbergerE, VolchkovV, ParagasJ et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A2000; 97:12289–12294 [View Article] [PubMed]
DetjeCN, MeyerT, SchmidtH, KreuzD, RoseJK et al. Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol2009; 182:2297–2304 [View Article] [PubMed]
ItoY, NagaiY, MaenoK. Interferon production in mouse spleen cells and mouse fibroblasts (L cells) stimulated by various strains of Newcastle disease virus. J Gen Virol1982; 62:349–352 [View Article]
CantellK, HirvonenS, KauppinenHL, MyllyläG. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. PestkaS. eds In Interferons New York, NY: Academic Press; 1981 pp 29–38
van den BroekMF, MüllerU, HuangS, ZinkernagelRM, AguetM. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev1995; 148:5–18 [View Article] [PubMed]
BarchetW, CellaM, OdermattB, Asselin-PaturelC, ColonnaM et al. Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo. J Exp Med2002; 195:507–516 [View Article] [PubMed]
RaabenM, Groot KoerkampMJA, RottierPJM, deHC. Type I interferon receptor-independent and -dependent host transcriptional responses to mouse hepatitis coronavirus infection in vivo. BMC Genomics2009; 10:350 [View Article]
FragkoudisR, BreakwellL, McKimmieC, BoydA, BarryG et al. The Type I interferon system protects mice from Semliki forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons. J Gen Virol2007; 88:3373–3384 [View Article] [PubMed]
OhkaS, IgarashiH, NagataN, SakaiM, KoikeS et al. Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol2007; 81:7902–7912 [View Article] [PubMed]
PrakashA, SmithE, LeeCK, LevyDE. Tissue-specific positive feedback requirements for production of type I interferon following virus infection. J Biol Chem2005; 280:18651–18657 [View Article] [PubMed]
MullerR, SaluzzoJF, LopezN, DreierT, TurellM et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg1995; 53:405–411 [View Article] [PubMed]
MurrayC, ÉWG, O’LoughlinE, LyonsA, SherwinE et al. Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I:C. Brain Behav Immun2015; 48:274–286 [View Article]
GommetC, BillecocqA, JouvionG, HasanM, Zaverucha do ValleT et al. Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice. PLoS Negl Trop Dis2011; 5:e1421 [View Article] [PubMed]
deBS, VerhelstJ, van den HoeckeS, SmetA, SchotsaertM et al. A GFP expressing influenza A virus to report in vivo tropism and protection by a matrix protein 2 ectodomain-specific monoclonal antibody. PLoS One2015; 10:e0121491 [View Article]
KumarH, KawaiT, KatoH, SatoS, TakahashiK et al. Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med2006; 203:1795–1803 [View Article] [PubMed]
LazearHM, LancasterA, WilkinsC, SutharMS, HuangA et al. Irf-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog2013; 9:e1003118 [View Article] [PubMed]
BaldridgeMT, LeeS, BrownJJ, McAllisterN, UrbanekK et al. Expression of ifnlr1 on intestinal epithelial cells is critical to the antiviral effects of interferon lambda against norovirus and reovirus. J Virol2017; 91: [View Article] [PubMed]
YinZ, DaiJ, DengJ, SheikhF, NataliaM et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol2012; 189:2735–2745 [View Article] [PubMed]
OnoguchiK, YoneyamaM, TakemuraA, AkiraS, TaniguchiT et al. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem2007; 282:7576–7581 [View Article] [PubMed]
LiuB, ChenS, GuanY, ChenL. Type III interferon induces distinct socs1 expression pattern that contributes to delayed but prolonged activation of JAK/STAT signaling pathway. Implications for treatment non-response in HCV patients. PLoS One2015; 10:e0133800
ZhouZ, HammingOJ, AnkN, PaludanSR, NielsenAL et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol2007; 81:7749–7758 [View Article] [PubMed]
BenderS, ReuterA, EberleF, EinhornE, BinderM et al. Activation of type I and III interferon response by mitochondrial and peroxisomal MAVS and inhibition by hepatitis C virus. PLoS Pathog2015; 11:e1005264 [View Article] [PubMed]
OdendallC, DixitE, StavruF, BierneH, FranzKM et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat Immunol2014; 15:717–726 [View Article] [PubMed]
CrottaS, DavidsonS, MahlakoivT, DesmetCJ, BuckwalterMR et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog2013; 9:e1003773 [View Article] [PubMed]
FlemingSB. Viral inhibition of the ifn-induced JAK/STAT signalling pathway: Development of live attenuated vaccines by mutation of viral-encoded ifn-antagonists. Vaccines (Basel)2016; 4: [View Article] [PubMed]
WaiblerZ, AnzagheM, FrenzT, SchwantesA, PöhlmannC et al. Vaccinia Virus-Mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol2009; 83:1563–1571 [View Article] [PubMed]